多西紫杉醇
前列腺癌
医学
联合疗法
癌症研究
PI3K/AKT/mTOR通路
药理学
蛋白激酶B
癌症
前列腺
免疫系统
内科学
信号转导
免疫学
化学
生物化学
作者
Sixu Zhou,Baogui Wang,Yingying Wei,Pengcheng Dai,Yan Cao,Ying-Yi Xiao,Hongmei Xia,Chunlin Chen,Yin Wu
出处
期刊:Cancer Biomarkers
[IOS Press]
日期:2024-01-17
卷期号:: 1-13
摘要
Docetaxel is a yew compound antitumor agent with accurate antitumor efficacy, but its application is limited due to the high and serious adverse effects, and finding effective combination therapy options is a viable strategy. Immune checkpoint inhibitors have become hotspots in enhancing anti-tumor immunity by blocking immune checkpoint signaling pathways, but their response rate to monotherapy use is not high and the efficacy is minimal.To explore the anti-tumor effects and mechanisms of the combination of PD-1 inhibitors and Docetaxel through in vivo experiments and develop a feasible combination treatment for the therapy of prostate cancer.Tumor-bearing mice were subcutaneously injected with 0.1 ml RM-1 cells. Treatment were taken when the tumor growed up to 3 mm, after which the tumor and spleen were removed to test the antitumor effect with Flow cytometric (FACS) analysis, Immunohistochemistry, Western Blot.In this experiment, we found that PD-1 inhibitors combined with Docetaxel had a synergistic effect on mouse prostate cancer, inhibited the growth of prostate cancer, improved survival and reduced adverse reactions, increased spleen and tumor infiltrative CD4+ and CD8+ T cells, especially in group combination with low-dose Docetaxel, and were related to the PI3K/AKT/NFKB-P65/PD-L1 signaling pathway.Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI